Amid the Rise of the Delta Variant, Here's My Top Coronavirus Vaccine Stock to Buy

The first reason Pfizer is the best of the bunch is simply that it's the leader in the coronavirus vaccine market, at least in terms of revenue. The company also said that it expects roughly $33.5 billion in sales from BNT162b2 in 2021, which is much higher than the $26 billion Pfizer had projected in its first-quarter earnings release. Moderna (NASDAQ: MRNA) is the only rival that even comes close to Pfizer, with estimated sales of $19.2 billion for its vaccine, mRNA-1273 (this estimate will, in all likelihood, be revised upward).